Latest news


Publication of results showing that the PCI technology can significantly improve vaccination treatment in a melanoma model

Posted on Dec 9, 2014

Lysaker, 9 December 2014 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that results from animal studies with PCI Biotech’s proprietary technology photochemical internalization (PCI) at University Hospital Zurich have been accepted for publication in Journal of Controlled Release, a high impact pharmaceutical scientific journal. The article has the title “Photosensitisation facilitates cross-priming of […]

PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million

Posted on Dec 9, 2014

Lysaker, 9 December 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Reference is made to PCI Biotech Holding ASA’s (“PCI Biotech” or the “Company”) stock exchange announcements on […]

Third quarter 2014 results

Posted on Nov 18, 2014

Lysaker, 18 November 2014 – PCI Biotech’s Q3 2014 report is attached below : Q3 2014 Report